From left to right: Baldur Sveinbjørnsson (Lytix Biopharma), Daniel Heinrich (AHUS), Hege Edvardsen (LMI) and Ketil Widerberg (Oslo Cancer Cluster) discussed how clinical trials can become an integrated part of cancer treatment in Norway.

Integrating clinical trials in cancer treatment

Fremtidens Kreftbehandling: Kreft og kliniske studier. Et veikart for bedre kreftbehandling.

How can we make clinical trials an integrated part of cancer treatment in Norway so that more patients can gain access to new and better treatments?

We arranged a webinar with key experts and politicians to answer this question. Watch the entire webinar on Youtube:

“The number of patients that get considered to participate in clinical studies in Norway is too low and it is difficult to arrange clinical studies across borders in the Nordics. This is unacceptable, but how can we change it?” This is how the moderator Ketil Widerberg, general manager of Oslo Cancer Cluster, set the scene for our first webinar, which was live-streamed from Kreftforeningens Vitensenter in Oslo.

A visionary plan

The Norwegian Ministry of Health and Care Services has said that clinical studies should be an integrated part of patient treatment in Norway. This is especially relevant when it comes to the advent of new cancer treatments and the fact that the number of clinical trials is decreasing in Norway. The Ministry is now working on a Clinical Studies Action Plan to be completed in 2020.

Maiken Engelstad, Deputy Director General of The Department of Specialist Health Care Services, gave a presentation on its contents so far. An overarching goal is to get more, useful clinical studies to Norway, so that more patients can receive better treatments, and ultimately achieve a more efficient health service.

Engelstad mentioned many important aspects to achieve this. For example, to create more collaborations between the industry and public sector, with NorCRIN as a “one-stop-shop” for clinical studies. Engelstad stressed that Norway needs to build capacity, so that feasibility, recruitment and approval is accelerated. Engelstad also talked about building competency, by including clinical research, gene therapy and artificial intelligence in education. Moreover, Engelstad wants to increase the multitude of different studies, catering to both big and small patient groups, vulnerable patients, assessing both new and established treatments, and conducting the trials both locally, nationally and internationally. 

“We need to look to Norway’s advantages, such as real world data, which can be used from designing the drugs to implementing new therapies in the clinic.” Maiken Engelstad

Engelstad said that there needs to be a national and regional framework in place to achieve this, with regulations, financing, infrastructure and competency. Engelstad finally highlighted that one of the biggest challenges is to achieve a cultural change towards conducting clinical trials in Norway.

The tangle of rules

The legal framework that regulates clinical studies in the Nordics is very difficult to navigate for patients who wish to participate in and for companies that wish to arrange clinical trials. Wenche Reed, Head of Research in The Section for Research, Innovation and Education at Oslo University Hospital, talked about how complicated it is to interpret the regulations. 

“There are many laws to consider when conducting clinical studies. It is not easy to navigate the legal landscape – not even for lawyers!” Wenche Reed

Reed explained that the advent of personalized medicine in cancer is challenging the division between patient treatment and clinical research. Moreover, the ethical and legal framework for handling big data is being challenged, because of new developments using artificial intelligence in diagnostics.

Tearing down the barriers

The introductory presentations were followed by a lively panel discussion, divided into three sections. The first section included a video message from Tone Skår, project manager in VIS Innovation and founder of the MED.hjelper project and #SpørOmKliniskeStudier social media movement. Skår emphasised the importance of informing patients of the possibility of participating in trials and creating incentives for doctors and hospitals to run the trials.

Sigrid Bratlie, Special Adviser in The Norwegian Cancer Society, commented that a cultural change is needed. Bratlie said we need to look at concrete cases to learn how to conduct successful clinical studies in cancer personalised medicine.

Bratlie highlighted that Norway has world-class cancer research milieus, especially in cell therapy, but the total number of clinical trials is dwindling. Europe risks falling far behind the US and China, because of the complicated legal framework.

“The Biotechnology Act is just one small piece of the puzzle. Soon there will be a hearing for the Genetechnology Act. We need to look at the bigger picture and how the different laws interact.” Sigrid Bratlie

The second part of the panel conversation turned to both clinicians and industry for their perspectives. Daniel Heinrich, Senior Consultant Oncologist at Akershus University Hospital and Head of The Norwegian Oncology Association, wants to offer his patients the opportunity to try new treatments, which potentially can be better than the standard treatment. Heinrich highlighted that it is difficult for patients that need to travel to different hospitals and private clinics for testing because the hospitals lack capacity. He said that the directives need to come from above, from hospital management, the Directorate of Health and the politicians.

“It is almost impossible to include patients in studies in other countries now. Often it is difficult to understand why!” Daniel Heinrich

Baldur Sveinbjørnsson, Chief Scientific Officer in Norwegian cancer start-up Lytix Biopharma, has tried to arrange a clinical trial in Norway, but found that it was better to conduct it from a hospital in Copenhagen. When patient recruitment was too slow and costs were mounting every day, Sveinbjørnsson travelled around the Nordics to attract patients. There was great interest, but the differing regulations and processes in the Nordic countries put a stop to recruitment.

“We have started looking towards the US and filed an application to the authorities to conduct our next clinical study there.” Baldur Sveinbjørnsson

Hege Edvardsen, senior adviser in Legemiddelindustrien (LMI), thinks Norwegian companies should be able to conduct their trials in Norway. Edvardsen said we need to establish a “one-stop-shop” for clinical studies in Norway. Edvardsen said that the pharmaceutical industry often turns to the most successful cancer centres and hospitals when placing their clinical trials.

“Dedicated enthusiasts are the ones running the clinical studies, but we need targeted financing, so the people doing the work are acknowledged.” Hege Edvardsen

The final part of the panel discussion included two politicians’ visionary perspectives for the future.

Marianne Synnes Emblemsvåg, politician for The Conservative Party of Norway – Høyre, said she was touched by the ambitious plans in the Action Plan. Emblemsvåg commented that she is an impatient person, but that the bureaucratic process takes time to change.

“We need to market Norway in a way that makes us attractive for clinical trials.” Marianne Synnes Emblemsvåg

Emblemsvåg commented that there are many exciting developments considering artificial intelligence and diagnosing cancer, but that they come with some very challenging ethical considerations.

Tuva Moflag, politician for The Labour Party of Norway – Arbeiderpartiet, agreed that things take time to change. Moflag emphasised that part of the political work is to “clean up” some of the bureaucratic mess and to remove the legal barriers.

“We should have high ambitions for clinical studies, considering that we are a rich country and should assume responsibility for our patients.” Tuva Moflag

Moflag also stressed that there needs to be infrastructure, personnel and financing to complete it. Creating a culture of innovation, so that medical personnel feel they are part of something bigger than themselves.

The webinar ended with some final comments from Engelstad, who had been listening and taking diligent notes to bring with her in her work with the Action Plan going forward.

We want to direct a special thank you to all the meeting participants, to the organising partners and to everyone who followed the live stream.

Our next meeting in this series will take place this fall. More details will be published on our website closer to the event.

 

Event organisers:

 

 

 

Sign up to our monthly newsletter

 

Photo credit: Aline Ponce from Pixabay

May 17th Virtual Greeting

Pavlova, Photo by Alice Ponce from Pixabay.

”Gratulerer med dagen” (Congratulations!) on Norway’s Constitution Day from the entire Oslo Cancer Cluster team.

As a prelude to the May 17th celebrations, Oslo Cancer Cluster hosts an annual networking breakfast for our cluster’s members, neighbours in Oslo Cancer Cluster Innovation Park and the wider oncology community.

The Norwegian Constitution Day Breakfast 2020 has been adapted in the form of this virtual greeting as we observe social distancing together.

The team at Oslo Cancer Cluster and Oslo Cancer Cluster Incubator would like to wish Norwegians everywhere “Gratulerer med dagen!” with best wishes on this special day for Norway.

Oslo Cancer Cluster members in Norway and around the world, thank you for your support toward collective efforts to positively impact oncology research.

 

This is what it looked like when Tia (to the left) and Henrik (to the right) received homeschooling via digital classes from their teacher Monica Flydal Jenstad (bottom right corner) during corona lockdown.

Homeschooling for researchers-to-be

Henrik and Tia receive homeschooling during the corona lockdown.

This article was originally published in Norwegian on our School Collaboration website.

Even during the corona lockdown, the researcher students have received inspiring classes online, but they miss the practical work and are happy to soon return to school.

The researcher programme is an opportunity for upper secondary students who want to specialise in the natural sciences and the teaching is based on a combination of practical work and in-depth theory. So, how has home schooling been during corona lockdown? Digital classes in biology have replaced the usual work placements in professional research laboratories and performing experiments in school. We talked to the students Tia and Henrik, and their teacher Monica, to find out more.

CORONA UPDATE

This article was written before the Norwegian government released the positive news that students will return to school during week 20.

Since Ullern Upper Secondary School houses almost 1 000 students, they will return gradually to control the spread of COVID-19. The Researcher Programme starts on Wednesday 13 May and the class will be off to a flying start.

“The students will receive a lecture from an astrophysicist on their first day back. It was supposed to be delivered digitally, but now it might take place in the classroom, which will be extra special!” says Monica.

Both Monica and the students are looking forward to returning to the school. Henrik and Tia were hoping to begin school again during May and now they are getting their wish fulfilled.

“I think home schooling works. It is effective. The teachers have made great arrangements and we are learning new things,” says Henrik Corneliussen, who is in his first year of the Researcher Programme.

“I think it is going surprisingly well in many subjects, but it is difficult to stay motivated and focused on the teaching when we are doing so much on our own. Math is a bit more difficult now and biology is also challenging,” says Tia Morigaki Sauthon, who is in the same class as Henrik.

Monica Flydal Jenstad and Ragni Fet are Natural Science teachers and have both been cancer researchers. They are responsible for the new Researcher Programme at Ullern Upper Secondary School and teach biology and natural science to the class of 32 students for 10 hours every week.

Almost overnight, the teachers had to change their planned classes, because of the corona pandemic. They went from being physically present in the classroom – with all the available lab equipment and the possibility to perform experiments to exemplify different theories – to communicating with the whole class over the video-calling system Teams and teaching the students by using PowerPoint presentations and group tasks.

“Ullern Upper Secondary School is following the normal curriculum during homeschooling. When class begins, everyone checks into our Teams chatroom and says hi. Ragni or I deliver the teaching, usually through a lecture, and then the students complete tasks in a program called ‘OneNote’. We can see if the students are completing the tasks and help them if they are stuck or wondering about something,” Monica says.

Monica explains that life as a teacher has become more hectic and intense during corona lockdown, delivering classes in a digital format and being more available via messaging and calls over Teams.

Missing the practical aspects

Even though Henrik and Tia are generally happy with the digital classes, there are a few things they miss during homeschooling.

“I really miss the practical schoolwork, which we can barely do at all, because we lack access to equipment that we need to perform experiments at home. We have also missed out on many placements, which is a shame. I have luckily already participated in one placement, but it is sad for the students who haven’t had the opportunity,” Henrik says.

The Ullern students visited the Core Facility for Advanced Light Microscopy at Oslo University Hospital.

Image caption: Henrik, second person from the left, is one of the lucky students on the Researcher Programme, who has already participated in a placement. The other students in the picture are Peder, Isha and Christopher. The placement was with the research group for advanced cancer therapy in February. Photo: Elisabeth Kirkeng Andersen

“It is really sad that we have missed out on so much practical work, which was why I chose the Researcher Programme. Fortunately, we have done a few experiments at home. We have, among other things, made our own solar thermal collectors and learnt how to measure light strength in lux, which we have used to understand how to measure the distance from the Earth to the stars,” says Tia.

Monica shares the students’ feelings.

“The students were in the middle of their independent research projects when the school closed. Some had already performed experiments at home with plants that they could follow up, but other students were dependent on finishing their projects at school. The purpose was always for them to present the results of their research during a poster session, which is a presentation format that researchers use to show data and other findings from their research, but we have had to postpone this activity. Hopefully, we can complete it in June with the students’ mentors present,” Monica says.

The poster session is not the only thing the students have missed. Four placements with different research groups at Oslo University Hospital and the company Thermo Fisher Scientific, and three relevant lectures by researchers, were planned for the period they have been stuck at home.

“The students have missed out on many aspects of the Researcher Programme in this period, because it is difficult to perform the practical work, both in the regular teaching and in the form of placements. It is simply a more boring school day,” Monica says.

The corona pandemic itself can however be used in the teaching, both in mathematics to learn about exponential growth and in biology to learn about viruses.

Happy to return to school

Tia and Henrik really miss being in school together with the other students of the Researcher Programme and other friends, both at Ullern and outside of school.

“I look forward to meeting my friends again. I don’t see many of them now. I also look forward to getting started with the practical work at school, with experiments in the natural sciences and biology. It is really fun, and the teachers are good at organising interesting experiments and placements, in collaboration with Oslo Cancer Cluster,” says Henrik.

Tia also misses her friends a lot.

“Maybe what I look forward to the most is getting back to the normal everyday routine – going to school and being with friends. I talk to my friends over Teams and have one friend I meet a lot, but I miss being with many people at once,” says Tia.

She thinks the learning is more challenging from home.

“It is easier to ask for help in school. It is much more difficult to get a verbal explanation without being shown how everything is connected by the teacher, so I spend a lot of time trying to figure things out myself instead of asking for help,” says Tia.

The students are also sorely missed by their teachers.

“I miss them all and especially the contact with the students in a classroom setting, one-on-one. It is much more fun and better to follow the students directly, especially when they think the subject is a bit heavy,” says Monica.

Tia is still sure that even though the corona pandemic has had far-reaching consequences, not all of them are bad.

“I think it seems like everyone has made the best out of the situation. It could have gone much worse and been much worse. In many ways, I think this is a useful experience and, one way or another, something good will come of it,” says Tia.

Summary of postponed or cancelled plans for the students:

  • Poster session about their own research projects with the mentors
  • Lecture on screening of new-borns with Janne Strand, Child- and Youth Clinic, Oslo University Hospital
  • Lecture on structural biology and drug design with Bjørn Dalhus, Oslo University Hospital
  • Lecture on organising research with Barbra Noodt, Cancer Clinic, Oslo University Hospital
  • Placement with Thermo Fisher Scientific
  • Placement with Harald Stenmark at the Department of Molecular Cell Biology, Oslo University Hospital
  • Placement with Hans Christian Aas at Flow Cytometry Core Facilities at Oslo University Hospital
  • Placement with Bjørn Dalhus’ research group Structural Biology and DNA repair, Oslo University Hospital.

 

Sign up to our monthly newsletter

Ketil Widerberg, general manager of Oslo Cancer Cluster, gave input to the hearing on the changes to the Biotechnology Act in order to promote cancer innovation in Norway.

Research on gene-edited embryos allowed

Important cancer research into gene-edited human embryos will now be possible in Norway

Research on gene-edited human embryos will now be allowed in Norway, after a majority agreement has been reached among parties in the Norwegian Parliament. The news was given at a press conference on Thursday, when representatives from the three political parties Arbeiderpartiet, Fremskrittspartiet and Sosialistisk Venstre presented the amendments to the Biotechnology Act (“bioteknologiloven”). This is the act relating to the application of biotechnology in medicine.

The changes to the Biotechnology Act are good news for cancer patients and researchers, as they allow for research into gene-edited human embryos. This will give us important knowledge about how cancer arises and how to develop effective treatments against cancer.

Oslo Cancer Cluster gave input to these changes, during a hearing on 6 February 2020 at the Ministry for Health and Care Services. We emphasised that it is important that the regulations are in line with technological developments to promote research, so that we in the future have improved access to personalised cancer diagnostics and treatments.

“These are important changes to promote cancer innovation in Norway. It will help accelerate research into new cell therapies, which will benefit cancer patients both here in Norway and abroad,” said Ketil Widerberg, general manager of Oslo Cancer Cluster.

Gene technology is an important area in cancer research, with many recent break-through discoveries. By gene-editing human embryos, researchers can develop personalised cancer treatments and diagnostics.

Cell division in embryos and uncontrolled cell division in cancer cells is regulated by the same genes. That is why research on gene-edited human embryos will give us valuable knowledge about genetic diseases like cancer.

Gene technology can be used to create genetic changes and give us more knowledge about cell division. For example, researchers can insert genetic markers in DNA and follow the cell’s development from stem cell to cancer cell. They can also produce mutations in an embryo and study how cancer develops at an early stage.

You can read more about cancer research and gene-editing on the Cancer Research UK Science Blog.

It is important to note that the embryos used for research and gene-editing are not allowed to be implanted in a female uterus for pregnancy. This is in line with the current Swedish regulations on gene-edited human embryos.

The fact that gene-editing human embryos will be allowed in Norway means that we can attract world-class cancer clinical studies and deliver new personalised treatments to cancer patients.

The Norwegian Parliament (“Stortinget”) will officially vote on the amendments on 26 May 2020 and we will follow any further developments closely.

Sign up to our monthly newsletter

 

Foto: Helsenæringens Verdi 2020

Helsenæringens verdi 2020

Helsenæringens Verdi 2020

Helsenæringen er en dobbel mulighet for Norge: næringen kan løse mange av våre helse- og omsorgsutfordringer de neste tiårene og samtidig bli en av våre største næringer, med eksport til et globalt marked.

Den norske helsenæringen hadde en samlet omsetningsvekst på 4,7 prosent i 2018. Rapporten dokumenterer at denne veksten særlig var drevet av store selskaper i den norske helseindustrien. Bedriftene i alle bransjene i helsenæringen rapporterer om ytterligere vekst 2019, noe som resulterer i et vekstestimat for næringen som helhet på 6,2 prosent for 2019 – dette er høyere enn næringens gjennomsnittlige årlige vekst for de siste ti årene.

Bedriftene rapporterer samtidig om svært sterke forventninger til treårsperioden fra 2020 til 2022. Bedriftenes egne vekstprognoser for disse årene er imidlertid hentet inn før Koronakrisen utviklet seg til en global krise. Det er av den grunn svært høy usikkerhet knyttet til disse prognosene.

Koronakrisen er en «helsekrise». Dette gjør at krisen påvirker helsenæringen med en langt større variasjon mellom bransjer og segmenter enn for andre næringer. I rapporten redegjøres det både for segmenter i helsenæringen som aldri har opplevd høyere etterspørsel og aktivitet enn nå under Koronakrisen samt for bransjer og segmenter som har tilnærmet stoppet helt opp.

Den norske helsenæringen fremstår som godt forspent for videre vekst også i etterkant av Koronakrisen. Krisen har bidratt til å rette fokus på beredskap og innenlandsk produksjonskapasitet. En trend mot dette er ventet å styrke selskaper og produksjonsland som kan levere kvalitet, profesjonalitet og trygghet for leveranser, også i krisesituasjoner. Dette er en trend som bør kunne gagne Norge og norske helsebedrifter, både produsenter av legemidler eller medisinsk teknologi så vel som leverandører av helsetjenester.

Helsenæringens verdi 2020 dokumenterer at det er særlig er to ting bedriftene etterspør for å sikre videre vekst,

  • Markedstilgang – bedriftene i helsenæringen, både industri- og behandlingsbedriftene, trekker frem tilgang til offentlige anbud og konkurranse på like vilkår som den største flaksehalsen for videre vekst. Det er særlig mindre bedrifter og selskaper med inntekter fra både inn- og utland som opplever tilgangen på offentlige anbud som dårlig.
  • Skaleringskapital – det trekkes frem av et flertall av bedrifter at de savner støtteordninger som er innrettet mot skalering og internasjonalisering

Se lanseringen av Menon-rapporten

Les rapporten Helsenæringens Verdi 2020

Aktørene som står bak Menon-rapporten:

arrangørers logo

Computers with different software and programming language is necessary to learn about machine learning and artificial intelligence. PhD student Øyvind Sigmundsson Skøyen explains to Jakob, August, Magnus and Jørgen how to program the game Snake so that the snake always survives.

Programming to understand artificial intelligence

Students learning Artificial Intelligence, Machine Learning and Neural Networks

This article was originally published in Norwegian on our School Collaboration website.

How can programming, artificial intelligence and machine learning help us understand the human brain?

Four students from Ullern Upper Secondary School spent two days in the beginning of March on a placement in the Department of Physics at the University of Oslo. Jakob, August, Jørgen and Magnus learned how to program the snake in the game Snake to survive. At the same time, they learned about artificial intelligence, neural networks and machine learning.

Every spring, Professors Anders Malthe-Sørenssen and Marianne Fyhn at the University of Oslo receive eight students from Ullern Upper Secondary School on a placement.

Marianne Fyhn’s research group consists of some of the leading neuroscientists in the world. The four biology students Chiara, Eline, Tora and Eilin from Ullern Upper Secondary School spent the placement training rats and learned how research on rats can provide valuable knowledge about the human brain.

Anders Malthe-Sørenssen is the Director of CCSE (the Center for Computing in Science Education), where the students Magnus Trandokken, August Natvik, Jørgen Hamsund and Jakob Weidel were on another placement.

“There are three PhD students here, who are teaching the Ullern students. At the end of the day, they will gain a better understanding of what artificial intelligence is. We wish to explain the concept to them and give them an insight into what machine learning, neural networks and programming are,” said Malthe-Sørenssen.

  • Scroll to the bottom of this page to read the definitions for machine learning, neural networks and artificial intelligence.

Malthe-Sørenssen and the PhD students tested a new teaching tool on the Ullern students. If it is successful, more students will be able to access it to learn about artificial intelligence. Malthe-Sørenssen and his research group also try to improve the teaching of advanced mathematics, physics and programming in upper secondary schools.

Students learning artificial intelligence, machine learning and neural networks

Øyvind Sigmundsson Skøyen (in the middle) was one of the PhD students that taught the students from Ullern Upper Secondary School. Here, he is helping Jakob Weidel, who is in his first year. To the right is August Natvik, who is graduating this year. Photo: Elisabeth Kirkeng Andersen

Making the snake immortal

Jakob, Magnus, August and Jørgen programmed the game Snake in the programming language Python. This is a programming language that is available for free, an “open source”. You can download it here.

The point of the game Snake is to keep a snake alive for as long as possible. It lives in a square, where it eats candy so that its tail grows. The purpose of the game is to make sure the snake doesn’t crash into itself while it is growing because if it crashes, the snake dies. But it is not that easy. Try it yourself here.

“The students will program the snake so that it can learn where it is smart to move to eat the candy, while at the same time avoiding to crash into its growing tail. It is a good way to understand a little artificial intelligence and machine learning,” said Malthe-Sørenssen.

The three PhD students Sebastian Winther-Larsen, Øyvind Sigmundsson Skøyen and Even Marius Nordhagen were there to teach the Ullern students.

Øyvind had just finished showing the students how to programme the snake when it was Even’s turn to teach.

“What du you already know about machine learning?” Even asked.

“I have seen a little bit on YouTube,” Jakob replied.

“I know the theory, but I haven’t tried it myself,” Magnus said.

Even explained that he would present the theories behind machine learning and neural networks first, and then let the students create a neural network for Snake.

“Linear regression – a theory we often use in mathematics – is a simple form of machine learning. It is about producing a function that gives us the best line between two points. We use something called the method of least squares,” Even said.

Ullern students learning artificial intelligence, machine learning and neural networks.

Espen Marius Nordhagen (to the right) explains to the students from Ullern that regression is a simple form of machine learning. August Natvik is following closely. Photo: Elisabeth Kirkeng Andersen

Even explained that machine learning is used in image analysis. A computer can be taught to recognise and see the difference between several objects in a picture. The objects can be cars, bikes, humans, or other things. The computer can then be taught to create the images, which are then called generative models. Voice recognition, such as the virtual assistant Siri for iPhone users, is also based on machine learning, just like self-driving cars and buses.

“In order to understand artificial intelligence, you have to know what a neural network is. The concept is inspired by biology, neuroscience, and how human beings learn and remember. A neural network is a simplification of the human brain. The brain is in reality much more complicated,” Even explained.

“What is actually the difference between machine learning and artificial intelligence?” Jørgen asked.

Even explained that regression is machine learning, but not artificial intelligence.

“If you have a neural network with several layers, a so-called ‘deep neural network’, it is artificial intelligence. Then you will observe that something is happening with the data you receive from the neural network, it will be something you do not understand and cannot model, but it is consistent with reality,” Even said.

Learned new subjects

Magnus, August and Jørgen are all in the third year and have specialised in the natural sciences, with different combinations of mathematics, physics, technology, research, programming and computer modelling.

After graduating, all three of them will go to military school. Afterwards, Jørgen and Magnus are tempted to study at NTNU.

“The Industrial Economics programme at NTNU seems really good. Maybe I will combine it with the Entrepreneurship Programme, which is also at NTNU. Then I can start my own company after I finished studying. I am also thinking about a career in the military,” said Magnus.

The Ullern students agreed that the placement at the Department of Physics had been difficult, but fun and educational too.

“They are really good at teaching here. It has been difficult, because we haven’t studied these subjects before and everything new is always difficult,” said Jørgen.

Jakob Weidel is still in his first year and is thinking about studying the same subjects as the other three Ullern students. He was asked to participate in the placement after he helped Tom Werner Halvårsrød, the IT administrator at Ullern Upper Secondary School, to programme Excel sheets, which are used in the school.

“I have made a few apps and developed a few websites and used different types of programming languages. I have never used Python before, so it has been fun to learn something new,” said Jakob.

(image caption) Anders Malthe-Sørenssen is a professor at CCSE (the Centre for Computing in Science Education) at the University of Oslo. He and his research group are active in many different areas of research, including improving how physics is taught and understanding how the brain works through advanced mathematical models. Photo: Elisabeth Kirkeng Andersen.

Anders Malthe-Sørenssen is a professor at CCSE (the Centre for Computing in Science Education) at the University of Oslo. He and his research group are active in many different areas of research, including improving how physics is taught and understanding how the brain works through advanced mathematical models. Photo: Elisabeth Kirkeng Andersen

Neural networks and neuroscience

Malthe-Sørenssen’s and Fyhn’s research groups collaborate in a field of biology and physics, which is about research into how the human brain works and neural networks, in the projects DigiBrain and CINPLA. CINPLA is an acronym for Centre for Integrative Neuroplasticity.

“Here at the Department of Physics, we create computer models of neural networks. Then, we compare our models with Marianne’s discoveries about how the brain works from her studies on rats and mice. So far, we have seen that our models give a good picture of what is actually happening in the brain, but we are far from finished,” says Malthe-Sørenssen.

His popular research group receives over 1 000 job applications every year, but they want to keep prioritising student placements.

“We are dedicated to contributing to improving the programming skills in schools. One of our employees has developed the new subject and the syllabus for programming and computer modelling, which will be implemented in upper secondary schools by autumn 2020. Programming will then be used to teach several subjects, including mathematics,” Malthe-Sørenssen says.

He thinks it is good to contribute to raising the level of skills in the local schools around the Department of Physics at the University of Oslo.

What is a placement?

Oslo Cancer Cluster and Ullern Upper Secondary School have an active school collaboration project. The collaboration gives students at the school the opportunity to take part in work placements at different companies and research groups at Oslo University Hospital, at the University of Oslo and with members of Oslo Cancer Cluster.

On the placements, the students get to learn about different subject areas directly from experts and they get the opportunity to do practical laboratory work. The purpose of the placements is to give the students an insight into the practical everyday life of different professions and what career opportunities that different academic degrees hold.

DEFINITIONS

Neural Networks: A neural network is a group term for data structures, and their algorithms, that has been inspired by the way nerve cells in the brain are organised. Neural networks are among the key concepts in machine learning and artificial intelligence.

Machine learning: Machine learning is a special area within artificial intelligence, where you use statistical models to help computers to find patterns in large data quantities. The machine “learns” instead of being programmed.

Artificial intelligence: Artificial intelligence is information technology that adapts its own activity and therefore seems intelligent. A computer that is able to solve assignments without instructions from a human on how to do it, has artificial intelligence.

Sign up to our monthly newsletter

 

Our funding support: up to €60 000 per SME

Our EU project DIGI-B-CUBE offers funding support of up to €60 000 per SME, for small to medium-sized enterprises that may be struggling during the corona crisis.

The COVID-19 pandemic represents an unprecedented challenge for healthcare systems and societies worldwide. There is an urgent need for novel diagnostics solutions, integrated detection systems and biosensing technologies that would, in a rapid, specific and efficient way, support the identification and tracking of infection chains and acquired immunity. Biological and biomedical imaging technologies are also essential for addressing many research questions, such as those related to SARS-CoV-2 infections, from basic research at the molecular and cellular level to medical applications and diagnostics. In addition, Biobanking processes are crucial in the race towards a COVID-19 vaccine and development of treatment options.

There is an urgent need to support Small and Medium-sized Enterprises (SMEs) capable of delivering innovation projects addressing the broad range of COVID-19 related challenges.

Through DIGI-B-CUBE project, we are announcing our funding support for SMEs to fight against COVID-19 through cross-sectoral collaborative projects. DIGI-B-CUBE offers direct financial support up to €60,000 per SME from relevant sectors including healthcare, medicine, biotech, biopharma, IT, robotics, automation, electronics, and nanotech. DIGI-B-CUBE supports digital innovations and solutions for the reconfiguration of the Medical Diagnostics and related value chains (depicted in the diagram below) towards a Health Economy 4.0 with a special focus on Biobanking, Bioimaging, Biosensing and related industries.

digibcube graphics

Given below are the details of the DIGI-B-CUBE open call: 

Project Name: Digital Enterprise Innovations for Bioimaging, Biosensing and Biobanking Industries (DIGI-B-CUBE)

Open Call Title DIGI-B-CUBE Open Call for Proposals for Innovation Projects (DIGI-B-CUBE-IA-2020-2021)

Open Call Publication Date: 22 April 2020

Deadlines:

Voucher Type 1st Deadline 2nd Deadline
Prototyping Voucher 29 July 2020 at 17:00 (CET) 03 February 2021 at 17:00 (CET)
Customised Solution Innovation Voucher 29 July 2020 at 17:00 (CET) 03 February 2021 at 17:00 (CET)
Continuous Open Call
Co-working Disruption Lab Voucher From 28 October 2020 to 27 October 2021, 17:00 (CET)

Expected Duration of Participation:

Voucher Type Project Runtime
Prototyping Voucher 1 to 3 months
Customised Solution Innovation Voucher 2 to 6 months
Co-working Disruption Lab Voucher 0.5 to 2 months

Maximum Funding Request per Proposal:

Voucher Type Max. funding per SME Max. funding per project
Prototyping Voucher €20 000 €60 000
Customised Solution Innovation Voucher €50 000 €150 000
Co-working Disruption Lab Voucher €10 000 €10 000

Purpose of the Vouchers and Respective Applicant Group:

Voucher Type Purpose Applicant Group
Prototyping Voucher Support to prototype or conceptualise a solution (proof of concept, feasibility study) for a digitalization challenge in the Medical Diagnostics and related value chains. Consortium consisting of minimum 2 SMEs and maximum 3 organizations;

From at least 2 different sectors (Example: An SME from healthcare/medicine/biotech/biopharma + An SME from IT and related sectors)

Customised Solution Innovation Voucher Support to jointly develop a novel product/service based on an existing proven concept that addresses a digitalization challenge in the Medical Diagnostics and related value chains. Consortium consisting of minimum 2 SMEs;

From at least 2 different sectors (Example: An SME from healthcare/medicine/biotech/biopharma + An SME from IT and related sectors)

Co-working Disruption Lab Voucher Support to further advance a successfully completed customised solution innovation voucher project in an incubator / accelerator / co-working space of the DIGI-B-CUBE clusters’ network (or) in labs, technical and innovation facilities of other relevant SMEs. One SME from a completed Customized Solution Innovation Voucher project consortium + a host organisation (host does not receive direct funding from this voucher)

Evaluation Process:

The evaluation process takes max. 4 weeks starting from the respective cut-off date/deadline. The applicant/s will receive an e-mail about the outcome of the assessment directly after the assessment is finalised.

Target Group:

SMEs from the following sectors are eligible to apply for DIGI-B-CUBE vouchers:

  • healthcare / medicine / biotech / biopharma
  • IT and related sectors (robotics, automation, electronics, nanotech etc)

Submission Language: English

Web address for full open call informationhttps://digibcube.eu/open-calls/

Web address for proposal submissionshttps://digibcube.eu/collaborative-platform/

E-mailinfo@digibcube.eu

Indicative budget for the call: Total budget €2 700 000. The following budget planned across the deadlines may change based on the number and quality of the applications received.

Voucher Type 1st Deadline 2nd Deadline
Prototyping Voucher approx. €360 000 approx. €240 000
Customised Solution Innovation Voucher approx. €1 050 000 approx. €700 000
Continuous Open Call
Co-working Disruption Lab Voucher approx. €150 000

Contact (Coordinator):

Dr. Gupta Udatha

Director (Digital & EU)

Oslo Cancer Cluster

Oslo, Norway

Email: gupta.udatha@oslocancercluster.no

Funding opportunities for health and IT SMEs

Digi-b-cube logo

DIGI-B-CUBE, funded under the European Union´s Horizon 2020 Programme, aims to unlock the cross-sectoral collaborative potential of SMEs by combining e.g. Artificial Intelligence (AI), Cognitive Computing Digital Technologies (CCDT) with the Bioimaging-Biosensing-Biobanking (B-CUBE) and related value chains to deliver market sensitive disruptive technologies and generating innovative solutions that enhance patient-centred diagnostic work-flows.

The project provides support to SMEs through matchmaking, coaching, digital transformation services and equity-free funds up to €60,000 per SME. The support helps SMEs design solutions and develop new products and services to accelerate innovations in personalised medicine. SMEs can access these services and apply for funding under the DIGI-B-CUBE Voucher Scheme by registering on the DIGI-B-CUBE Collaborative Platform at platform.digibcube.eu.

Use the DIGI-B-CUBE Collaborative Platform at platform.digibcube.eu to:

  • Get to know other organisations and identify collaboration partners online or during matchmaking events;
  • Register for DIGI-B-CUBE events;
  • Access services (digital maturity assessment tool, knowledge repository, training, competence network and board programme) to facilitate your digital transformation;
  • Apply for funding through the DIGI-B-CUBE Voucher Scheme;
  • Get follow-up coaching by the cluster organisations regarding further existing support measures and additional funding schemes.

Participate in the DIGI-B-CUBE Events to:

  • Identify value chains and associated challenges for SMEs for their digital innovation and collect data on existing processes and management systems;
  • Evaluate identified value chains and associated challenges for SMEs and develop customised solutions;
  • Take part in matchmaking events and face-to-face meetings to find collaboration partners from the IT and/or Health sector to apply for funding for joint digital innovation projects that address value chain issues;
  • Take part in digital transformation activities and follow-up coaching in order to successfully develop and scale-up digital innovation products and services.

Receive funding through the DIGI-B-CUBE Voucher Scheme

Benefit from four types of vouchers to tackle digitalisation challenges and:

  • Build cross-sectoral and cross-border partnerships composed of businesses that are challenge-owners and solution-providers;
  • Contribute to new Health industries, new digital Health services, effective Medical Diagnostics that will lead to Precision Medicine, Preventive Medicine and Healthcare Transformation.

Travel Voucher

Up to €2,000 per voucher
Up to €6,000 per SME

Get reimbursed for your travel costs (transportation, accommodation and event fees) incurred for attending DIGI-B-CUBE events. Applications must be submitted prior to the event.

Available from 20th September 2019 to 28th February 2022


Prototyping Voucher

Up to €20,000 per SME
Up to €60,000 per project

Receive funding to prototype or conceptualise a solution for a digitalisation challenge in the Medical Diagnostics and related value chains. Consortia consisting of minimum two SMEs and maximum three organisations from at least two different sectors will be funded.

1st Deadline: 29th July 2020
2nd Deadline: 3rd February 2021


Customised Solution Innovation Voucher

Up to €50,000 per SME
Up to €150,000 per project

Receive funding to jointly develop a novel product/service based on an existing proven concept that addresses a digitalisation challenge in the Medical Diagnostics and related value chains. Consortia consisting of minimum two SMEs from at least two different sectors will be funded.

1st Deadline: 29th July 2020
2nd Deadline: 3rd February 2021


Co-working Disruption Lab Voucher

Up to €10,000 per SME/project

Receive additional funding to further advance a successfully completed Customised Solution Innovation Voucher project in an incubator / accelerator / co-working space of the DIGI-B-CUBE clusters’ network (or) in labs, technical and innovation facilities of other relevant SMEs. Consortia can include one SME from a completed project consortium and a host organisation.

Available from 28th October 2020 to 27th October 2021

Note: An SME can apply for multiple vouchers but the overall maximum funding per SME is €60,000.


Who can apply?

SMEs that are interested in cross-sectoral collaborations, aiming to integrate innovations from IT into the B-CUBE industries and related value chains, to accelerate the goals of personalised medicine. SMEs should be established in one of the EU member states or H2020 associated countries.

Register on the DIGI-B-CUBE Collaborative Platform at: platform.digibcube.eu

 

 

EU disclaimer

New member: PharmaRelations

Image of Oslo Cancer Cluster Innovation Park

In this series, we will be introducing the new members that have joined our oncology ecosystem in the last six months. Follow us for a new article next week!

Have you heard of PharmaRelations? One of our newest members works with recruiting talents to the Life Sciences.

A cornerstone in the development of cancer treatments is to secure talented professionals to the right jobs. That is why recruitment companies are one of the essential parts of our membership organisation. PharmaRelations is one of the latest additions.

PharmaRelations was founded in Sweden in 1997 and started their recruitment services in 2004. The Oslo office opened in 2018 and their mission is to grow people and companies in Life Science with their portfolio of Talent Services. We talked with Sverre Slaastad, Head of Recruitment and Talent Specialist at PharmaRelations, about why they are involved in Oslo Cancer Cluster.

Could you briefly describe your company and the role it is taking in cancer/health?

“With our extensive network and candidate database, we are the market leader in Life Science recruitment in the Nordic countries. The Life Sciences is our area of expertise, including pharmaceuticals, MedTech, Biotech, Labtech, Animal Health and Dental care,” said Sverre Slaastad.

Why did you join Oslo Cancer Cluster?

“We want to help Oslo Cancer Cluster by recruiting the best people for their members and thereby improving health in society overall,” said Sverre Slaastad.

Pharma relations logo

 

Sign up to our monthly newsletter

Ketil Widerberg, general manager, Oslo Cancer Cluster, supports Abelias proposal to mobilise the health industry in the fight against corona. Photo: Stig Jarnes

Health clusters to help against corona pandemic

Ketil Widerberg, general manager, Oslo Cancer Cluster

Let the health industry contribute to the fight against COVID-19!

This week, Abelia wrote a letter to the Minister of Health and Care Services and the Minister of Trade, Industry and Fisheries, appealing that they use the Norwegian health industry against the corona pandemic.

The corona pandemic has put Norway and its health services in an extraordinary situation. The health industry will play a central role in how this pandemic is handled. There will be a need to think of new ways to deliver health services, in order to alleviate the health sector in the long and short term.

Health tech companies can meet this need by delivering innovative solutions, but we need to utilise this potential quickly and efficiently. A strategic collaboration between the public health services and the up-and-coming health tech companies can achieve this.

Abelia, Oslo Cancer Cluster and the other Norwegian health clusters are uniquely positioned to connect and mobilise members of the health industry. A fast-working advisory council could help to look at the needs the corona crisis creates, to discover innovative solutions, and to identify relevant market opportunities for Norway.

“The corona pandemic has shown the important role the health industry has. Now more than ever, it is crucial to use and understand health data, to implement novel digital solutions in our health services and to speed up drug development times,” said Ketil Widerberg, general manager, Oslo Cancer Cluster.

The proposal in the letter is to assemble an advisory council consisting of representatives from the Norwegian health clusters (Oslo Cancer Cluster, Norway Health Tech, The Life Science Cluster and Norwegian Smart Care Cluster) in close collaboration with the governmental funding bodies (Innovation Norway, the Research Council of Norway and SIVA).

Sign up to our monthly newsletter